After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
The money will be awarded from IU’s Grand Challenges Program, a new push that is designed to tackle “major and large-scale problems facing humanity” that can only be addressed by multidisciplinary research teams.
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
The Indiana Blood Center said it has been forced to defer up to 30 percent of donors at some post-spring break blood drives because they had traveled to areas where the Zika virus is being transmitted.
Indianapolis-based chemical manufacturer Vertellus Specialties Inc. has expanded its production capacity by 80 percent to keep up with customer demand for DEET, a common active ingredient in mosquito and tick repellents.
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.